posted
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Releases Corporate Video Presentation Highlighting Company's Pioneering Stem Cell Science and Therapeutic Development Programs Monday January 22, 11:02 am ET CEO Outlines Initiatives to Translate Stem Cell-Based Treatments from Laboratory to Clinic to Treat Range of Disease
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC - News), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, invites investors to view a new video providing an overview of the Company's unique technologies as well as its overall strategies to develop breakthrough medical therapies for a variety of serious diseases and degenerative conditions. ADVERTISEMENT
In the video, William M. Caldwell IV, Chairman and Chief Executive Officer of Advanced Cell Technology, discusses the Company pioneering innovations relating to the field of human embryonic stem cells (hESc).
posted
Advanced Cell Technology Releases Corporate Video Presentation Highlighting Company's Pioneering Stem Cell Science and Therapeutic Development Programs
Jan 22, 2007 11:02:03 (ET)
ALAMEDA, Calif., Jan 22, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, invites investors to view a new video providing an overview of the Company's unique technologies as well as its overall strategies to develop breakthrough medical therapies for a variety of serious diseases and degenerative conditions.
In the video, William M. Caldwell IV, Chairman and Chief Executive Officer of Advanced Cell Technology, discusses the Company pioneering innovations relating to the field of human embryonic stem cells (hESc).
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Advanced Cell Technology, Inc. Initiation of Coverage and Informational Review Issued by Scimitar Equity Research of ACTC Proprietary Technology and Development Programs
Jan 29, 2007 10:07:00 (ET)
BOSTON, Jan 29, 2007 /PRNewswire via COMTEX/ -- Scimitar Equity Research, Inc. today issued a new Informational Review on Advanced Cell Technology, Inc. (ACTC, Trade ) entitled, "The Road to Commercial Development of New Therapies from Stem Cells."
Advanced Cell Technology (ACT) is a biotechnology company applying human embryonic stem (hES) cell technology in the emerging field of regenerative medicine. ACT is developing novel stem cell-based treatments and cures to target a variety of serious diseases and injuries. ACTC's lead therapeutic development programs include stem cell based treatments for retinal disease such as macular degeneration; diseases of the blood, heart and circulatory system; and dermatological treatments for repair of skin damage from surgery, wounds and burns. ACT has entered development partnerships with leading institutions, and is pursuing additional partnerships with leading biotechnology companies and organizations worldwide. ACTC has announced plans to file in 2007 its first Investigational New Drug Application (IND) with the FDA to treat the eye condition known as macular degeneration.
The analyst research review of ACTC is available on Scimitar's website: www.scimitarequity.com .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com . For investor-specific information and resources, visit
Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about Advanced Cell Technology (ACTC, Trade ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: hwm*scimitarequity.com
SOURCE Scimitar Equity Research, Inc.
Henry W. McCusker, Director of Research of Scimitar Equity Research, Inc., +1-617-559-1080, fax: +1-617-559-1083, e-mail: hwm*scimitarequity.com
posted
Advanced Cell Technology Senior Scientist Dr. Robert Lanza Awarded for Outstanding Contributions to Biology by Brown University Biotech Group
Feb 2, 2007 08:33:07 (ET)
ALAMEDA, Calif., Feb 02, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, has announced that Dr. Robert Lanza, the Company's Vice President of Research and Scientific Development, has been recognized for his groundbreaking research and contributions in stem cell science and biology with a special award from Brown University's Biotechnology Interest Group.
The Brown University biotech group made the award for "Outstanding Contribution in Contemporary Biology" to Dr. Lanza at the organization's 5th Annual Biotech Expo, held February 1, 2007, at Brown's Providence, R.I., campus. Dr. Lanza also delivered a keynote address at the conference.
Dr. Lanza is a noted pioneer in the field of stem cell science, with more than 25 years' experience in the application of stem cells in regenerative medicine. He has published several hundred papers, patents and innovations relating to stem cell science, among them ACTC's Single Cell Blastomere method to derive human embryonic stem cells without harming the donor embryos' potential for life.
"This award helps bring additional notice to the stem cell industry at a point when the field is entering an exciting period of clinical development," said Dr. Lanza. "At ACTC and at institutions around the world, we are focused on the development of powerful new products that have the potential to revolutionize treatment for a growing number of serious diseases and injuries."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California, and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com or The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Advanced Cell Technology Announces Collaboration with the Casey Eye Institute at Oregon Health and Science University
Feb 6, 2007 08:33:21 (ET)
ALAMEDA, Calif., Feb 06, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that it has entered into a sponsored research agreement with Oregon Health and Science University. The Company is collaborating with Dr. Raymond Lund, Dr. Richard Weleber and Dr. Peter Francis at the Casey Eye Institute to conduct preclinical studies for its Retinal Pigment Epithelium ("RPE") Program. Specifically, the research team is conducting a dosage study utilizing the Company's RPE cells in the Royal College of Surgeons ("RCS") rat model and plans to conduct similar studies in other rodent models of retinal degenerative disease. The Company is also in discussions with the Oregon Health and Science University team in regard to future plans for a Phase I human clinical trial.
Dr. Peter Francis, Assistant Professor of Ophthalmic Genetics and Co-Director of the Oregon Retinal Degeneration Center at the Casey Eye Institute said, "We are very excited to be working with Advanced Cell Technology. This area or research shows great promise for the treatment of a number of blinding conditions."
Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology responded, "We are very excited to be working with the entire team at the Casey Eye Institute. Drs. Lund, Weleber and Francis bring a wealth of experience to our program in the area of retinal degenerative disease. We are also honored to enter into our first collaboration with Oregon Health and Science University, which has clearly distinguished itself as a leader in biomedical research."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Acquires Intellectual Property Assets of Infigen, Inc. Thursday February 8, 8:44 am ET Landmark Merger of Embryonic Stem Cell Patent Estates
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that it has acquired the intellectual property assets of its former competitor Infigen, Inc. relating to somatic cell nuclear transfer (SCNT), parthenogenesis, and other related technologies. A total of 26 issued patents and numerous pending patent applications were acquired for a combination of cash and shares of common stock. The acquisition provides ACTC with exclusive ownership rights to critical technologies in regenerative medicine and the merger of assets is expected to strengthen ACTC's intellectual property position in the drive towards commercialization of embryonic stem cell and SCNT technology. ADVERTISEMENT
"This tactical acquisition is a part of our long-term plan to become one of the leading companies in the field of regenerative medicine," said William M. Caldwell, IV, Chief Executive Officer of Advanced Cell Technology. "We intend to use these technologies to further our product development and use the exclusive rights under these patents to protect the company and, as appropriate, leverage these patents through licensing transactions with potential strategic partners."
Dennis McCormick, Chairman of Infigen, Inc., commented, "We are pleased to complete this transaction and believe Advanced Cell Technology is one of the preeminent stem cell companies with the ability to commercialize this technology."
Infigen, Inc. heavily invested in its intellectual property portfolio relating to animal cloning and filed some of the earliest and most strategic patents in fundamental steps related to SCNT. One such critical step in SCNT is the activation of oocytes - a process designated "parthenogenetic activation". Egg cells must be activated for SCNT to be successful. In a previous royalty-bearing cross license, ACTC acquired freedom to operate under the Infigen patents in the field of human cell therapy. However, with this acquisition, royalty obligations are removed and ACTC owns the patents exclusively for building its business in regenerative medicine and for use in licensing animal applications.
"We believe the Infigen intellectual property, when merged with our existing proprietary technologies, creates an impressive patent estate. The patents include fundamental technologies useful in the production of any type of cell or tissue matched to the patient through the process of SCNT," said Dr. Michael West, ACTC's President and Chief Scientific Officer. "In addition, in our experience, we believe that this portfolio provides us with a dominant patent position in the production of human embryonic stem cells by parthenogenesis wherein stem cells are made from an egg cell without fertilization or SCNT.
Dr. West continued, "Combining these patents under one roof should simplify the regenerative medicine patent landscape. We will license out the animal applications for use in agriculture and animal science and use the human technologies for our internal programs including applications in the retina, vascular system, and dermatology."
Aquetong Capital Advisors assisted Infigen, Inc. in connection with this transaction.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------------------------------------------------------------------- Source: Advanced Cell Technology, Inc.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?
IP: Logged |
posted
Thanks IMAKE, it is an indicator that they will at some time take profits but I would think they have had a taste of their potential from where they were just a couple months ago. I would think they would hold and watch this grow. They are looking for sponsorship from some of the big boys. Keeping in mind who is working in this sector in the US one competitor, Neurotech from RI has some major supporters. IMO Advanced Cell is setting themselves up to attract more institutional support also as they gain more visibility. Just getting started IMO. http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_ticker?ticker=actc Could have some pretty good dips as they gain better footing but long term worth holding a position imo. A couple major pharms pick this up and away she goes.
Just like anything else - it has its piece of pie in the risk area. Watching the form 4’s. Issuing the convertibles… “We elected to make the monthly redemption payments due on March 1, 2007 under certain of our convertible debentures maturing September 14, 2008” makes it look even better eh?
posted
Advanced Cell Technology Names Noted Biotech Industry Executive Dr. Pedro Huertas, as Chief Development Officer to Manage the Clinical Development and Regulatory Approval Process for its Stem Cell-Based Therapeutic Products
Feb 12, 2007 10:18:24 (ET)
ALAMEDA, Calif., Feb 12, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) names Pedro Huertas, MD, PhD, as Chief Development Officer responsible for overseeing the development of the Company's programs to create novel stem cell-based therapeutics, from the pre-clinical stage through clinical development and regulatory approval.
Dr. Huertas, who trained at Harvard-MIT, brings with him extensive experience in medicine, biotechnology start-ups and academic science. Most recently he was Chief Medical Officer at both StemCells, Inc. and Novazyme Pharmaceuticals, Inc. where he managed and directed medical, clinical and regulatory affairs for both companies. At Novazyme, Dr. Huertas positioned and developed the program that was the focus of the company's $185 million acquisition by Genzyme Corporation, which gained FDA approval in 2006 for the first Pompe biotherapeutic agent. At StemCells, Inc. he crafted and filed a successful IND for human neural stem cell transplantation in neuronal ceroid lipofuscinosis.
William M. Caldwell, IV, Chief Executive Officer of Advanced Cell commented, "Dr. Huertas brings a rare combination of scientific excellence and proven business experience in the biotechnology industry to Advanced Cell, and we are fortunate to have him join us at this very important juncture in our Company's development. His expertise will be an invaluable asset to the Company as we accelerate our efforts to develop and commercialize medically valuable stem cell-based therapies and products."
Dr. Huertas said, "Embryonic stem cells are an enormously powerful platform in medical science and offer unparalleled promise in treating some of the cruelest diseases. I look forward to joining Mr. Caldwell, Dr. West, Dr. Lanza and the other members of the talented team, as we work together to develop Advanced Cell's exciting therapeutic programs into the clinic and address the needs of many patients."
Dr. Heurtas has served as a Director of Strategic Development for Genzyme Corporation where he filed a successful biologics license application (BLA) to register Fabrazyme(TM), which achieved worldwide sales of $305 million in 2005 for the treatment of Fabry disease. At Genzyme, Dr. Huertas also conducted a pivotal phase III multi-national trial for Fabry disease and managed its clinical portfolio in related rare genetic diseases.
Most recently, Dr. Huertas served as Chief Strategy and Development Officer at Amicus Therapeutics Inc., where he was recruited to design, implement and manage product development trajectory for pharmacological chaperones. At Amicus, Dr. Huertas was responsible for overall research and development, preclinical and clinical development activities, and also formed Scientific and Medical Advisory Boards. He also established and managed a network of academic, industrial and governmental thought leaders for Amicus.
Dr. Huertas received a Doctor of Medicine degree from Harvard Medical School/ Massachusetts Institute of Technology where he was awarded the Becton Dickinson Research Scholarship and James H. Robinson Memorial Prize in Surgery. He completed his Doctor of Philosophy in Cell and Developmental Biology from Harvard University and also holds a Masters in Business Administration from MIT's Sloan School of Management. As a practicing physician, Dr. Huertas' positions include appointments at McLean Hospital, Massachusetts General Hospital and Harvard University Health Services.
He is a member of the Sloan Fellows Board of Governors, Sloan School of Management at MIT. He is a Charter Member, Advisory Board, of the Division of Health Sciences and Technology Program at Harvard Medical School-MIT and Founding Member, and Member of the Board of Directors of the Biomedical Entrepreneurship Program, at the Sloan School of Management, MIT.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
Advanced Cell's Michael West, Ph.D., Highlights ACTCellerate Platform, A Means of Accelerating the Differentiation of Cells from Human Embryonic Stem Cells, at 2nd Annual Stem Cell Summit
Feb 13, 2007 08:36:03 (ET)
ALAMEDA, Calif., Feb 13, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Michael West Ph.D., President and Chief Scientific Officer highlighted the Company's ACTCellerate Platform, yesterday, at the 2nd Annual Stem Cell Summit, in San Diego. While the Company's core focus is advancing its therapies related to the eye, vascular system, and skin, the Company believes this platform could augment the potential product applications from what many believe to be the most powerful cell, the human embryonic stem cell.
Human embryonic stem cells (hESC) are the first cells cultured in the laboratory capable of becoming every cell type in the human body. Therefore, the emerging field of regenerative medicine holds great promise for the treatment of many currently untreatable diseases. Despite that potential, researchers have not previously demonstrated efficient means of producing a large array of therapeutically-useful cell types in a pure and scalable form that allows them to be tested for potential human therapeutic use. The Company's proprietary ACTCellerate platform was invented by the Company as a means of accelerating the differentiation of cells from human embryonic stem cells, thereby expanding potential products made from embryonic stem cell technology.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
posted
institutional support has gone from 1% to 4% just in the past couple weeks. Not saying we couldn't use a nice dip to add but long term this is lookin better and better. jmho.
posted
Advanced Cell Applauds $3 Billion Stem Cell Research Program, Proposition 71, Upheld Monday By A California Appeals Court
Feb 28, 2007 10:41:18 (ET)
ALAMEDA, Calif., Feb 28, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) applauds the $3 Billion Stem Cell Research Program, Proposition 71, upheld Monday by a California appeals court. In a unanimous 3-0 ruling judges said Proposition 71 "suffers from no constitutional or other legal infirmity."
William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell Technology, commented, "California's Proposition 71 may be the world's largest single backer of research in stem cells. We believe a capital infusion could dramatically benefit the stem cell industry, and will fund translational programs, designed to enter the clinic in the near term. We are very proud of Governor Schwarzenegger and California's leadership in helping to maintain a competitive environment for commercial research and development in the stem cell field. We are also fortunate to be headquartered in the great state of California as Advanced Cell works to accelerate its stem cell therapies to the bedside."
Monday, in a public statement, Governor Schwarzenegger said, "Today's ruling is a victory - I always believed the courts would uphold the will of California voters. Stem cell research holds our best promise to find a cure for debilitating illnesses, like Parkinson's disease and diabetes. I'm also proud of California's leadership - we have already awarded the first round grants to researchers to begin work on this potentially life-saving science."
According to the New York Times, Robert N. Klein, chairman of the board overseeing the stem cell program, said the decision was so strong that he thought the California Supreme Court would decline to hear the case if the ruling were appealed and if the Supreme Curt turned away the case, the state could being issuing bonds as soon as 120 days from now.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Eek!]](eek.gif)
![[Cool]](cool.gif)
![[Smile]](smile.gif)
